Advertisement

Annals of Hematology

, Volume 97, Issue 6, pp 967–975 | Cite as

Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation

  • Xiaosu Zhao
  • Zhidong Wang
  • Guorui Ruan
  • Yanrong Liu
  • Yu Wang
  • Xiaohui Zhang
  • Lanping Xu
  • Xiaojun Huang
  • Yingjun ChangEmail author
Original Article

Abstract

In this study, using multiparameter flow cytometry (FCM), we investigate the impact of minimal residual disease prior to transplantation (pre-MRD) on the transplant outcomes of AML patients with fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutation. A total of 20 patients who received HLA-matched sibling donor transplantation (MSDT) and 63 patients who received unmanipulated haploidentical hematopoietic stem cell transplantation (haplo-HSCT) were enrolled. Patients were classified into four groups based on the status of pre-FCM: group 1 with positive pre-FCM before MSDT, group 2 with negative pre-FCM before MSDT, group 3 with positive pre-FCM before haplo-HSCT, and group 4 with positive pre-FCM before haplo-HSCT. The results showed that patients in group 1 had the highest cumulative incidence of relapse (2-year CIR, 75.0%), the lowest leukemia-free survival (2-year LFS, 33.3%), and the overall survival (2-year OS, 25.0%) among all four groups. The other three groups of patients had comparable CIR (2-year CIR: group 2 vs. 3 vs. 4, 12.5% vs. 31.3% vs. 22.2%, P > 0.05) and LFS (2-year LFS: group 2 vs. 3 vs. 4, 87.5% vs. 62.5% vs. 66.5%, P > 0.05). Multivariate analysis indicated that disease status (> CR) and pre-MRD were associated with a higher CIR and a lower LFS when patients were classified by pre-MRD and transplant type. Our results suggested that AML patients with FLT3-ITD were able to be separated into high-risk and low-risk relapse groups based on pre-MRD, as determined by multiparameter FCM. Haplo-HSCT might overcome the negative impact of pre-MRD on patient outcomes compared to MSDT. These results require further investigation in prospective study with large numbers of cases.

Keywords

Acute myeloid leukemia Allogeneic hematopoietic stem cell transplantation Minimal residual disease Multiparameter flow cytometry FLT3-ITD 

Notes

Acknowledgments

We thank all of the faculty members who participated in these studies. We would also like to thank American Journal Experts (https://www.aje.cn/) for assistance in editing this manuscript.

Author contributions

Contribution: Y.-J.C. designed the study; X.-S. Z., Z.-D.W., and Y.-J.C. collected, analyzed the data, and drafted the manuscript; all authors contributed to data interpretation, manuscript preparation, and approval of the final version.

Funding information

This work was supported (in part) by the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (Grant No. 81621001), the National Natural Science Foundation of China (Grant No. 81670175), the Scientific Research Foundation for Capital Medicine Development (2016-1-4082), and the Beijing Key Laboratory for Hematopoietic Stem Cell Transplantation.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Abdelhamid E, Preudhomme C, Helevaut N, Nibourel O, Gardin C, Rousselot P, Castaigne S, Gruson B, Berthon C, Soua Z, Renneville A (2012) Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res 36(3):316–323.  https://doi.org/10.1016/j.leukres.2011.11.002 CrossRefPubMedGoogle Scholar
  2. 2.
    Annesley CE, Brown P (2014) The biology and targeting of FLT3 in pediatric leukemia. Front Oncol 4:263CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Anthias C, Dignan FL, Morilla R, Morilla A, Ethell ME, Potter MN, Shaw BE (2014) Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant 49(5):679–683.  https://doi.org/10.1038/bmt.2014.9 CrossRefPubMedGoogle Scholar
  4. 4.
    Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB (2016) Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol 34(4):329–336.  https://doi.org/10.1200/JCO.2015.63.3826 CrossRefPubMedGoogle Scholar
  5. 5.
    Bornhauser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C, A. S. s. group (2007) Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 109(5):2264–2265 author reply 2265CrossRefPubMedGoogle Scholar
  6. 6.
    Candoni A, De Marchi F, Zanini F, Zannier ME, Simeone E, Toffoletti E, Chiarvesio A, Cerno M, Fili C, Patriarca F, Fanin R (2017) Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. Exp Hematol 49:25–33.  https://doi.org/10.1016/j.exphem.2017.01.005 CrossRefPubMedGoogle Scholar
  7. 7.
    Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ (2017) Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol 10(1):134.  https://doi.org/10.1186/s13045-017-0502-3 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, Wang FR, Han W, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ (2016) Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft-versus-host disease after haploidentical transplantation. J Clin Oncol 34(16):1855–1863.  https://doi.org/10.1200/JCO.2015.63.8817 CrossRefPubMedGoogle Scholar
  9. 9.
    DeZern AE, Sung A, Kim S, Smith BD, Karp JE, Gore SD, Jones RJ, Fuchs E, Luznik L, McDevitt M, Levis M (2011) Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 17(9):1404–1409.  https://doi.org/10.1016/j.bbmt.2011.02.003 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD, European L (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474.  https://doi.org/10.1182/blood-2009-07-235358 CrossRefPubMedGoogle Scholar
  11. 11.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956.  https://doi.org/10.1016/j.bbmt.2005.09.004 CrossRefPubMedGoogle Scholar
  12. 12.
    Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, Linch DC (2005) No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 106(10):3658–3665.  https://doi.org/10.1182/blood-2005-03-1323 CrossRefPubMedGoogle Scholar
  13. 13.
    Hourigan CS, Karp JE (2013) Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 10(8):460–471.  https://doi.org/10.1038/nrclinonc.2013.100 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W (2007) Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 92(3):414–417.  https://doi.org/10.3324/haematol.10570 CrossRefPubMedGoogle Scholar
  15. 15.
    Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu DP (2009a) Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 15(2):257–265.  https://doi.org/10.1016/j.bbmt.2008.11.025 CrossRefPubMedGoogle Scholar
  16. 16.
    Huang XJ, Liu DH, Liu KY, Xu LP, Chen YH, Wang Y, Han W, Chen H (2008a) Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 28(3):276–283.  https://doi.org/10.1007/s10875-007-9166-z CrossRefPubMedGoogle Scholar
  17. 17.
    Huang XJ, Wang Y, Liu DH, Xu LP, Chen H, Chen YH, Han W, Shi HX, Liu KY (2008b) Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia—feasibility and safety study. J Clin Immunol 28(4):390–397.  https://doi.org/10.1007/s10875-008-9193-4 CrossRefPubMedGoogle Scholar
  18. 18.
    Huang XJ, Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, Han W, Shi HX (2009b) Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant 44(5):309–316.  https://doi.org/10.1038/bmt.2009.26 CrossRefPubMedGoogle Scholar
  19. 19.
    Levis M (2013) FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematol Am Soc Hematol Educ Program 2013:220–226.  https://doi.org/10.1182/asheducation-2013.1.220 Google Scholar
  20. 20.
    Levis M, Small D (2003) FLT3: ITDoes matter in leukemia. Leukemia 17(9):1738–1752.  https://doi.org/10.1038/sj.leu.2403099 CrossRefPubMedGoogle Scholar
  21. 21.
    Meshinchi S, Arceci RJ, Sanders JE, Smith FO, Woods WB, Radich JP, Alonzo TA (2006) Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood 108(1):400; author reply 400–400; author reply 401CrossRefGoogle Scholar
  22. 22.
    Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, Small D, Berg KD (2003) Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 5(2):96–102.  https://doi.org/10.1016/S1525-1578(10)60458-8 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F (2012) Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica 97(8):1242–1245.  https://doi.org/10.3324/haematol.2012.062638 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, Lucid C, Vnencak-Jones CL, Greer JP, Savani BN (2012) Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant 47(12):1535–1537.  https://doi.org/10.1038/bmt.2012.88 CrossRefPubMedGoogle Scholar
  25. 25.
    Shah NN, Borowitz MJ, Steinberg SM, Robey NC, Gamper CJ, Symons HJ, Loeb DM, Wayne AS, Chen AR (2014) Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 20(7):1033–1039.  https://doi.org/10.1016/j.bbmt.2014.03.028 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99(12):4326–4335.  https://doi.org/10.1182/blood.V99.12.4326 CrossRefPubMedGoogle Scholar
  27. 27.
    Venditti A, Maurillo L, Buccisano F, Del Poeta G, Mazzone C, Tamburini A, Del Principe MI, Consalvo MI, De Fabritiis P, Cudillo L, Picardi A, Franchi A, Lo-Coco F, Amadori S (2003) Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 17(11):2178–2182.  https://doi.org/10.1038/sj.leu.2403138 CrossRefPubMedGoogle Scholar
  28. 28.
    Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk E, Chien JW, Gopal AK, Appelbaum FR, Pagel JM (2011) Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 29(9):1190–1197.  https://doi.org/10.1200/JCO.2010.31.8121 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, Sorror ML, Wood BL, Storb R, Appelbaum FR, Sandmaier BM (2015) Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 29(1):137–144.  https://doi.org/10.1038/leu.2014.173 CrossRefPubMedGoogle Scholar
  30. 30.
    Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, Han W, Shi HX, Huang XJ (2011) Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 17(6):821–830.  https://doi.org/10.1016/j.bbmt.2010.08.023 CrossRefPubMedGoogle Scholar
  31. 31.
    Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, Fan ZP, Wu DP, Huang XJ (2015) Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 125(25):3956–3962.  https://doi.org/10.1182/blood-2015-02-627786 CrossRefPubMedGoogle Scholar
  32. 32.
    Wood BL (2013) Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol 999:123–136.  https://doi.org/10.1007/978-1-62703-357-2_8 CrossRefPubMedGoogle Scholar
  33. 33.
    Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ (2012) Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 119(14):3256–3262.  https://doi.org/10.1182/blood-2011-09-380386 CrossRefPubMedGoogle Scholar
  34. 34.
    Yang L, Han Y, Suarez Saiz F, Minden MD (2007) A tumor suppressor and oncogene: the WT1 story. Leukemia 21(5):868–876.  https://doi.org/10.1038/sj.leu.2404624 CrossRefPubMedGoogle Scholar
  35. 35.
    Zhao XS, Qin YZ, Liu YR, Chang YJ, Xu LP, Zhang XH, Huang XJ (2017) The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. Leuk Lymphoma 58(5):1135–1143.  https://doi.org/10.1080/10428194.2016.1239264 CrossRefPubMedGoogle Scholar
  36. 36.
    Zhao XS, Yan CH, Liu DH, Xu LP, Liu YR, Liu KY, Qin YZ, Wang Y, Huang XJ (2013) Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol 92(8):1111–1119.  https://doi.org/10.1007/s00277-013-1733-1 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Xiaosu Zhao
    • 1
    • 2
  • Zhidong Wang
    • 1
  • Guorui Ruan
    • 1
  • Yanrong Liu
    • 1
  • Yu Wang
    • 1
    • 2
  • Xiaohui Zhang
    • 1
    • 2
  • Lanping Xu
    • 1
  • Xiaojun Huang
    • 1
    • 2
  • Yingjun Chang
    • 1
    • 2
    Email author
  1. 1.Peking University People’s Hospital, Beijing Key Laboratory of Hematopoietic Stem Cell TransplantationPeking University Institute of HematologyBeijingChina
  2. 2.Collaborative Innovation Center of HematologyPeking UniversityBeijingChina

Personalised recommendations